Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study by P. Emery et al.
EXTENDED REPORT
Rituximab versus an alternative TNF inhibitor in
patients with rheumatoid arthritis who failed to
respond to a single previous TNF inhibitor:
SWITCH-RA, a global, observational, comparative
effectiveness study
P Emery,1,2 J E Gottenberg,3 A Rubbert-Roth,4 P Sarzi-Puttini,5 D Choquette,6
V M Martínez Taboada,7 L Barile-Fabris,8 R J Moots,9 A Ostor,10 A Andrianakos,11
E Gemmen,12 C Mpofu,13 C Chung,14 L Hinsch Gylvin,13 A Finckh15
Handling editor Tore K Kvien
▸ Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/
annrheumdis-2013-203993).
For numbered afﬁliations see
end of article.
Correspondence to
Professor Paul Emery, Institute
of Rheumatic and
Musculoskeletal Medicine,
University of Leeds, LMBRU
LTHT, Chapel Allerton Hospital,
Leeds LS7 4SA, UK;
p.emery@leeds.ac.uk
Received 22 May 2013
Revised 10 December 2013
Accepted 22 December 2013
Published Online First
17 January 2014
To cite: Emery P,
Gottenberg JE, Rubbert-
Roth A, et al. Ann Rheum
Dis 2015;74:979–984.
ABSTRACT
Objectives To compare the effectiveness of rituximab
versus an alternative tumour necrosis factor (TNF)
inhibitor (TNFi) in patients with rheumatoid arthritis (RA)
with an inadequate response to one previous TNFi.
Methods SWITCH-RA was a prospective, global,
observational, real-life study. Patients non-responsive or
intolerant to a single TNFi were enrolled ≤4 weeks after
starting rituximab or a second TNFi. Primary end point:
change in Disease Activity Score in 28 joints excluding
patient’s global health component (DAS28-3)–erythrocyte
sedimentation rate (ESR) over 6 months.
Results 604 patients received rituximab, and 507 an
alternative TNFi as second biological therapy. Reasons for
discontinuing the ﬁrst TNFi were inefﬁcacy (n=827),
intolerance (n=263) and other (n=21). A total of 728
patients were available for primary end point analysis
(rituximab n=405; TNFi n=323). Baseline mean (SD)
DAS28-3–ESR was higher in the rituximab than the TNFi
group: 5.2 (1.2) vs 4.8 (1.3); p<0.0001. Least squares
mean (SE) change in DAS28-3–ESR at 6 months was
signiﬁcantly greater in rituximab than TNFi patients: −1.5
(0.2) vs −1.1 (0.2); p=0.007. The difference remained
signiﬁcant among patients discontinuing the initial TNFi
because of inefﬁcacy (−1.7 vs −1.3; p=0.017) but not
intolerance (−0.7 vs −0.7; p=0.894). Seropositive
patients showed signiﬁcantly greater improvements in
DAS28-3–ESR with rituximab than with TNFi (−1.6 (0.3)
vs −1.2 (0.3); p=0.011), particularly those switching
because of inefﬁcacy (−1.9 (0.3) vs −1.5 (0.4);
p=0.021). The overall incidence of adverse events was
similar between the rituximab and TNFi groups.
Conclusions These real-life data indicate that, after
discontinuation of an initial TNFi, switching to rituximab
is associated with signiﬁcantly improved clinical
effectiveness compared with switching to a second TNFi.
This difference was particularly evident in seropositive
patients and in those switched because of inefﬁcacy.
INTRODUCTION
Tumour necrosis factor-α (TNF-α) inhibitors are
effective treatments for patients with rheumatoid
arthritis (RA), improving signs and symptoms and
slowing or preventing structural damage.1
However, up to 40% of patients either fail to
respond adequately to these agents (primary inefﬁ-
cacy) or lose responsiveness over time (secondary
inefﬁcacy).2
Options available to patients with an inadequate
response to TNF inhibitors (TNF-IRs) include
treatment with an alternative TNF inhibitor and
switching to a biological therapy with a different
mode of action. Several studies have suggested that
beneﬁts may be gained by switching to an alterna-
tive TNF inhibitor.3–7 Among biological therapies
with an alternative mode of action, rituximab (an
anti-CD20 B-cell-depleting therapy), abatacept (a
T-cell costimulation blocking agent) and, more
recently, tocilizumab (anti-interleukin (IL)6 recep-
tor monoclonal antibody) have been demonstrated
to be signiﬁcantly better than placebo in TNF-IR
patients.8–10
Data on the comparative effectiveness of different
switching strategies are, however, limited. No
head-to-head trials have been conducted, and evalu-
ation of this question has been largely restricted to
indirect meta-analyses of the randomised controlled
trials noted above.11–14 Recent registry data provide
evidence that switching to rituximab may be
more effective than cycling to an alternative TNF
inhibitor.15–17
SWITCH-RA is a prospective, global, observa-
tional study, conducted in real-life practice condi-
tions, with the primary objective of comparing the
effectiveness of rituximab with an alternative TNF
inhibitor in patients with an inadequate response to
one previous TNF inhibitor. This paper reports the
6-month primary effectiveness and safety data from
SWITCH-RA.
METHODS
Study design and patient population
This was a prospective, global, multicentre, open-
label, observational study conducted in real-life
practice in adult patients with RA who were non-
responsive or intolerant to a single previous TNF
inhibitor. Patients were screened and enrolled up to
4 weeks after starting their second biological
therapy. In patients enrolled up to 4 weeks after the
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switch to a second biological therapy, the data collected at that
visit were those available at the time of the start of the second
biological therapy. Missing baseline Disease Activity Score in 28
joints (DAS28) values did not preclude enrolment. Patients
receiving a second biological therapy as part of a clinical trial
were excluded. No additional visits or laboratory tests were
required outside of routine clinical practice. Patients discontinu-
ing the second biological therapy continued to be observed for
the planned 12-month study period. Concomitant non-
biological disease-modifying antirheumatic drugs (DMARDs) or
other medications could be added at the investigator’s
discretion.
The Study Committee, a scientiﬁc board of leading inter-
national rheumatologists, designed the SWITCH-RA study and
assured its proper conduct. Data collection and statistical analyses
were conducted by an independent contract research organisa-
tion (Quintiles, Rockville, Maryland, USA). The study was con-
ducted in accordance with the principles of the Declaration of
Helsinki. Approval from the institutional review boards at each
study centre was received. All patients consented to data collec-
tion and review. ClinicalTrials.gov identiﬁer NCT01557348.
Assessments
Patients were followed for 12 months from the start of the
second biological therapy. Assessments included demographic
and clinical variables at the time of switching to the new bio-
logical therapy and reasons for discontinuation of the ﬁrst TNF
inhibitor. Reasons for discontinuation were classiﬁed as intoler-
ance, inefﬁcacy or other. Inefﬁcacy was further categorised as
primary inefﬁcacy (lack of initial clinical response to TNF
inhibitor treatment) or secondary inefﬁcacy (development of an
inadequate response over time after an initial clinical response).
Reasons classiﬁed as ‘other’ included patient choice.
Effectiveness was assessed using DAS28 excluding patient’s
global health component calculated with erythrocyte sedimenta-
tion rate (DAS28-3–ESR), a validated disease activity measure.18–
20 DAS28-3 was used rather than DAS28-4 because patient’s
global health assessment data were disproportionately under-
reported (particularly at baseline, in patients whose data were
captured retrospectively). Other variables assessed included ESR,
C-reactive protein (CRP), DAS28-3–CRP, swollen and tender
joint counts (SJC-28, TJC-28), patient global assessment of
disease, patient visual analogue scale pain score, Health
Assessment Questionnaire Disability Index (HAQ-DI) and dur-
ation of morning stiffness. Adverse events (AEs) reported in the
study were mapped to preferred terms in the Medical Dictionary
for Drug Regulatory Activities (MedDRA). The relationship of
AEs to study treatment was assessed by the investigator.
Owing to the non-interventional nature of the study, strict
adherence to visit windows was not feasible. DAS28-3–ESR
values at the nearest time point within a given window
(±2 months for the 6-month assessment) were used. Patients
were enrolled up to 4 weeks after starting their second bio-
logical therapy, resulting in a high rate of missing baseline
DAS28-3–ESR values. DAS28-ESR values directly reported by
the investigator were used to substitute for missing DAS28-3–
ESR values. If no values were available at the start of the second
biological therapy, the value at the end of the ﬁrst biological
therapy was used as baseline. An ‘as observed’ analysis was per-
formed to validate the robustness of the results.
Statistical analysis
The study did not enrol up to the planned sample size (631
patients with available data in each group). The retrospective
power based on the actual number of patients with a mean
change value in DAS28-ESR at 6 months (n=405 for rituximab
and 323 for alternative TNF inhibitor) was 70% to detect a dif-
ference of 0.3 DAS units, assuming a common SD of 1.6, using
a two-group t test with a 0.05 two-sided signiﬁcance level.
The primary end point was the mean change in DAS28-3–
ESR, 6 months after the change in biological therapy (considered
to be baseline). Six-month changes in clinical variables after the
initiation of the new therapy in the two treatment groups were
compared using analysis of covariance (ANCOVA), with adjust-
ment for unbalanced baseline characteristics and baseline value
of the outcome. Least squares (LS) means and p values were gen-
erated. As a sensitivity analysis, the end point was also analysed
using an ANCOVA model with adjustment for a propensity score,
calculated to determine the likelihood of selecting rituximab over
an alternative TNF inhibitor as the second biological therapy
driven by the patient’s baseline disease characteristics and poten-
tial confounding factors (see online supplementary text and
ﬁgure S1). A subanalysis was conducted to compare switching to
rituximab with an alternative TNF inhibitor in seropositive
(rheumatoid factor (RF) and/or anti-citrullinated protein anti-
body (ACPA) positive) and seronegative patients.
Safety results were summarised descriptively by treatment
group.
RESULTS
Patient disposition
A total of 1312 patients from 11 countries (Canada, Colombia,
France, Germany, Great Britain, Greece, Italy, Mexico, Norway,
Portugal and Spain) were screened, of whom 1239 were
enrolled in the study. Nine enrolled patients were excluded
from the analysis (missing information on second biological
therapy (n=3) and missing reasons for selection (n=6)). An add-
itional 119 patients were excluded as they had received more
than one previous TNF inhibitor, leaving 1111 patients valid
for analysis (full analysis population). Of these, 604 (54.4%)
received rituximab and 507 (45.6%) an alternative TNF inhibi-
tor as the second biological therapy. Patients could be enrolled
up to 4 weeks after starting the second biological therapy. As a
result, baseline DAS28-3–ESR scores were missing for about a
quarter of the patients (see online supplementary ﬁgure S2).
Data for 728 patients (rituximab, n=405; alternative TNF
inhibitor, n=323) who had baseline DAS28-3–ESR and had
completed 6 months after initiation of treatment with a second
biological agent were available for the primary end point ana-
lysis (primary effectiveness population).
Patient demographics and disease characteristics
In the full analysis population, the majority of patients were
female (79.1%); mean age was ∼55.5 years and mean disease
duration was ∼8.3 years. Patients in the two groups had received
a similar number of prior non-biological DMARDs and had
been on their ﬁrst TNF inhibitor for a similar length of time,
∼25 months (see online supplementary table S1). Baseline
disease characteristics were generally similar between the two
treatment groups, although patients who received rituximab
appeared to have higher disease activity in terms of SJC, TJC,
ESR and DAS28-3–ESR. Patients receiving rituximab were more
likely to be seropositive (RF+). Reasons for discontinuing initial
TNF inhibitor are given in table 1. Compared with patients dis-
continuing because of inefﬁcacy, patients discontinuing because
of intolerance had longer disease duration (mean (SD) 10.7
(8.7) vs 7.7 (6.6) years), and had been receiving their ﬁrst TNF
inhibitor for a shorter period of time (20.4 (24.0) vs 28.4
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(26.3) months). In addition, intolerant patients had signiﬁcantly
lower SJC, TJC, DAS28-3–ESR and HAQ-DI scores at the end
of their ﬁrst TNF inhibitor treatment (data not shown).
In this fully adjusted analysis, mean (SD) baseline DAS28-3–
ESR in the primary effectiveness population was signiﬁcantly
higher in patients who switched to rituximab than in those who
switched to an alternative TNF inhibitor: 5.2 (1.2) vs 4.8 (1.3),
p<0.0001 (table 2). This difference was also observed in
patients who discontinued their initial TNF inhibitor because of
inefﬁcacy (n=547) (5.3 (1.2) vs 4.9 (1.2), p<0.0001) and in
those who discontinued because of intolerance (n=168) (5.0
(1.3) vs 4.5 (1.4), p=0.029).
Effectiveness
Changes in clinical characteristics over 6 months are summarised
in table 3. The mean change in DAS28-3–ESR from baseline to
6 months was signiﬁcantly greater in the rituximab group
than in the alternative anti-TNF group (p=0.007) (table 3 and
ﬁgure 1). This difference remained statistically signiﬁcant among
the cohort of patients who discontinued initial TNF inhibitor
because of inefﬁcacy. However, among patients who discontin-
ued because of intolerance, there was no signiﬁcant difference
between rituximab and an alternative TNF inhibitor (ﬁgure 1).
A greater decrease in ESR was also observed in the rituximab
versus the alternative TNF inhibitor group, both overall and in
the inefﬁcacy cohort (−13.2 vs −7.0; p=0.009 and −10.0 vs
−4.3; p=0.038). SJC and TJC showed numerically greater
improvements with rituximab, although the differences were
not statistically signiﬁcant.
In a robustness analysis, in which no imputations of missing
DAS28 values were made, the mean change in DAS28-3–ESR
from baseline to 6 months remained signiﬁcantly greater in the
rituximab group versus the alternative TNF inhibitor group
(LS means −1.2 vs −0.9; p=0.033).
Subanalysis by serotype
Overall, 559 (77%) patients in the primary effectiveness popula-
tion were seropositive. Baseline DAS28-3–ESR scores were
Table 1 Reasons for discontinuation of previous TNF inhibitor
Reason Rituximab
Alternative TNF
inhibitor
All
patients
Full analysis population (n=604) (n=507) (n=1111)
Inefficacy 465 (77.0) 362 (71.4) 827 (74.4)
Primary* 214 (46.0) 115 (31.8) 329 (39.8)
Secondary* 244 (52.5) 233 (64.4) 477 (57.7)
Missing data 7 (1.5) 14 (3.9) 21 (2.5)
Intolerance 128 (21.2) 136 (26.6) 263 (23.7)
Other 11 (1.8) 10 (2.0) 21 (1.9)
Primary effectiveness
population
(n=405) (n=323) (n=728)
Inefficacy 311 (76.8) 236 (73.1) 547 (75.1)
Primary* 130 (41.8) 74 (31.4) 204 (37.3)
Secondary* 176 (56.6) 156 (66.1) 332 (60.7)
Missing data 5 (1.6) 6 (2.5) 11 (20.1)
Intolerance 89 (22.0) 79 (24.5) 168 (23.1)
Other 6 (1.2) 8 (2.5) 13 (1.8)
Values are number (%).
*Primary inefficacy, lack of initial clinical response to TNF inhibitor treatment;
secondary inefficacy, development of an inadequate response over time after an initial
clinical response.
TNF, tumour necrosis factor.
Table 2 Patient baseline demographics and clinical characteristics
(primary effectiveness population)
Characteristic
Rituximab
(n=405)
Alternative TNF
inhibitor (n=323) p Value*
Age (years), mean (SD) 56.5 (12.6) 54.7 (13.3) 0.0611
Female, n (%) 310 (76.5) 259 (80.2) 0.2376
RA duration (years), mean (SD) 9.1 (7.7) 7.8 (6.8) 0.1044
No of previous DMARDs,
mean (SD)
2.2 (1.1) 2.3 (1.3) 0.3853
Receiving methotrexate, n (%) 199 (49.1) 180 (55.7) 0.0769
Methotrexate dose (mg/week),
mean (SD)
13.3 (4.9) 14.4 (9.4) 0.1774
Receiving corticosteroid, n (%) 293 (72.3) 229 (70.9) 0.6666
Duration of previous TNF inhibitor
therapy (months), mean (SD)
27.4 (25.9) 26.3 (26.6) 0.6478
RF positive, n (%) 318 (84.1) 204 (65.6) <0.0001
ACPA positive, n (%) 172 (69.1) 133 (59.4) 0.0277
Seropositive (RF+ or ACPA+), n (%) 331 (81.7) 228 (70.6) 0.0004
DAS28-3–ESR, mean (SD) 5.2 (1.2) 4.8 (1.3) <0.0001
ESR (mm/h), mean (SD) 38.9 (26.7) 32.5 (24.7) 0.0023
CRP (mg/L), mean (SD) 26.1 (41.4) 23.8 (39.7) 0.4856
SJC (28 joints), mean (SD) 7.5 (5.5) 6.1 (5.6) 0.0024
TJC (28 joints), mean (SD) 10.2 (7.1) 8.2 (6.8) 0.0008
HAQ-DI, mean (SD) 1.5 (0.8) 1.3 (0.8) 0.0945
*Analysis of covariance or χ2 test.
ACPA, anti-citrullinated protein antibody; CRP, C-reactive protein; DAS28-3, Disease
Activity Score in 28 joints excluding patient’s global health component; DMARD,
disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ-DI,
Health Assessment Questionnaire Disability Index; RA, rheumatoid arthritis; RF,
rheumatoid factor; SJC, swollen joint count; TJC, tender joint count; TNF, tumour
necrosis factor.
Table 3 Mean changes in clinical characteristics from baseline to
6 months* (primary effectiveness population)
Change over 6 months
Rituximab
(n=405)
Alternative TNF
inhibitor
(n=323) p Value*
DAS28-3–ESR† −1.5 (0.2) −1.1 (0.2) 0.007
Improved by at least 0.6, n (%) 280 (69.1) 191 (59.1) 0.005
Improved by at least 1.6, n (%) 156 (38.5) 95 (29.4) 0.010
DAS28-3–CRP −1.4 (0.3) −1.3 (0.3) 0.538
ESR (mm/h) −13.2 (3.9) −7.0 (4.2) 0.009
CRP (mg/L) −29.1 (8.0) −29.9 (8.4) 0.876
SJC (28 joints) −3.3 (0.9) −2.8 (1.0) 0.417
TJC (28 joints) −5.7 (1.2) −4.5 (1.2) 0.113
Physician global assessment of
disease (mm)
−21.0 (6.1) −14.8 (6.7) 0.076
Patient global assessment of
disease (mm)
−17.0 (5.5) −10.2 (5.8) 0.044
Patient VAS pain score (mm) −15.7 (6.5) −10.8 (7.0) 0.203
HAQ-DI −0.6 (0.2) −0.5 (0.2) 0.337
Duration of morning stiffness (min) −19.0 (25.4) −4.3 (27.4) 0.325
Values are LS mean (SE).
*LS means and p values were based on analysis of covariance (ANCOVA) models
with change in outcome as the dependent variable and treatment group as the
independent variable, with controls for baseline value on the outcome variable, and
unbalanced baseline characteristics. p Values for counts were based on the Pearson’s
χ2 test.
†Sensitivity analysis results using ANCOVA with adjustment for the propensity to
receive treatment were rituximab −1.3 (0.1) and TNF inhibitor −1.0 (0.1) (p=0.006).
CRP, C-reactive protein; DAS28-3, Disease Activity Score in 28 joints excluding
patient’s global health component; ESR, erythrocyte sedimentation rate; HAQ-DI,
Health Assessment Questionnaire Disability Index; LS, least squares; SJC, swollen
joint count; TJC, tender joint count; TNF, tumour necrosis factor; VAS, visual
analogue scale.
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higher in the rituximab group than the alternative TNF inhibi-
tor group in both seropositive (mean (SD) 5.2 (1.2) vs 4.8 (1.3);
p<0.0001) and seronegative (5.3 (1.1) vs 4.7 (1.3); p=0.0019)
patients. After adjustment for baseline differences, seropositive
patients showed a signiﬁcantly greater improvement in
DAS28-3–ESR over 6 months with rituximab than with an alter-
native TNF inhibitor (table 4). The relative beneﬁt of rituximab
in seropositive patients was observed in patients who discontin-
ued their initial TNF inhibitor because of inefﬁcacy but not in
those who discontinued because of intolerance. Although sero-
negative patients also showed improvements in DAS28-3–ESR at
6 months, there was no signiﬁcant difference between the rituxi-
mab and alternative TNF inhibitor groups. The seronegative
group was, however, much smaller than the seropositive group,
and was therefore underpowered to detect small differences.
A similar pattern was seen with ESR as the outcome measure.
Seropositive patients receiving rituximab showed greater
changes in ESR (LS mean (SE)) over 6 months than those receiv-
ing an alternative TNF inhibitor (−14.4 (4.5) vs −7.3 (4.8);
p=0.006); corresponding results in seronegative patients were
−13.4 (8.3) vs −10.4 (9.0) (p=0.582).
Safety
A summary of safety is presented in table 5. The overall incidence
of AEs was similar in the rituximab and alternative TNF inhibitor
groups. The most commonly reported AEs (occurring in ≥2%
of patients) in the rituximab group were urinary tract infections
(4.8%), lower respiratory tract infections (2.8%), headache
(2.5%) and nausea (2.0%). In the alternative TNF inhibitor
group, the most frequent AEs were urinary tract infections
(3.2%), headache (3.2%), rash (3.0%), cough (2.8%), nausea
(2.6%), diarrhoea (2.4%), lower respiratory tract infections
(2.0%) and nasopharyngitis (2.0%). Infections were reported at a
similar rate in the two groups. Serious AEs were reported by 82
(13.6%) and 56 (11.0%) patients in the rituximab and alternative
TNF inhibitor groups, respectively, and most commonly occurred
within the musculoskeletal and connective tissue disorders
system organ class (rituximab, 21 patients (3.5%); alternative
TNF inhibitor, 22 patients (4.3%)). Serious infections were
reported more frequently with rituximab (25 events in 23
patients, 3.8%) than with alternative TNF inhibitor treatment
(nine events in nine patients, 1.8%) with corresponding
rates (95% CI) per 100 patient-years of 4.42 (2.86 to 6.52) vs
1.94 (0.89 to 3.68). Overall, the most common serious infections
(rituximab vs alternative TNF inhibitor group) were pneumonia
(0.5% (0.7% vs 0.2%)), urinary tract infection (0.4% (0.7% vs
0.0%)) and lower respiratory tract infection (0.3% (0.5% vs
0.0%)). There was one positive mycobacterium tuberculosis
complex test (T-SPOT; Oxford Immunotec, UK) in the alterna-
tive TNF inhibitor group. The patient received antituberculosis
agents (rifampicin and pyridoxine), and the event resolved
without sequelae. Malignancies (neoplasms—benign, malignant
and unspeciﬁed) were reported by nine rituximab patients
(1.5%) and 11 alternative TNF inhibitor patients (2.2%); two of
these events in each group were considered to be possibly related
to study treatment (stage 0 prostate cancer and Waldenstrom’s
macroglobulinaemia in the rituximab group and two patients
with squamous cell carcinoma of the skin in the alternative TNF
inhibitor group). Overall, seven (1.2%) and four (0.8%) patients
receiving rituximab and alternative TNF inhibitor, respectively,
died as a result of an AE during the study. None was considered
to be related to the study treatment.
DISCUSSION
Currently, there are no clear guidelines for managing patients
with RA with an inadequate response to initial TNF inhibitor
therapy. Consequently, decisions regarding further treatment
generally depend on factors such as patient choice and how
comfortable physicians are with the available alternatives.21 A
common strategy for managing TNF-IR patients involves
switching to a second TNF inhibitor. Although this strategy is
beneﬁcial in some patients,22 a number of studies have reported
reduced efﬁcacy with the second TNF inhibitor compared with
the ﬁrst and high rates of early discontinuation among patients
who switch.2
The primary effectiveness results from this global study
provide evidence from real-world practice that TNF-IR patients
Figure 1 Mean change in Disease Activity Score in 28 joints excluding
patient’s global health component–erythrocyte sedimentation rate
(DAS28-3–ESR) from baseline to 6 months. Analyses were adjusted for
baseline value and other covariates found to be statistically signiﬁcantly
different between the two groups at baseline. Values are DAS28-3–ESR
least squares means. TFNi, tumour necrosis factor inhibitor.
Table 4 Changes in DAS28-3–ESR at 6 months according to serotype (primary effectiveness population)
Seropositive patients (n=559) Seronegative patients (n=169)
Rituximab Alternative TNF inhibitor p Value Rituximab Alternative TNF inhibitor p Value
All patients −1.6 (0.3) −1.2 (0.3) 0.011 −1.3 (0.4) −1.1 (0.4) 0.449
Inefficacy −1.9 (0.3) −1.5 (0.4) 0.021 −0.5 (0.6) −0.2 (0.7) 0.472
Intolerance −0.5 (0.5) −0.5 (0.5) 0.997 −2.1 (1.2) −1.9 (1.3) 0.815
Values are LS mean (SE).
Patient numbers (all/inefficacy/intolerance): seropositive, rituximab 331/253/74 and TNF inhibitor 228/171/51; seronegative, rituximab 74/58/15 and TNF inhibitor 95/65/28. LS means
and p values were based on analysis of covariance models with change in outcome as the dependent variable and treatment group as the independent variable, with controls for
baseline value on the outcome variable, and unbalanced baseline characteristics.
DAS28-3, Disease Activity Score in 28 joints excluding patient’s global health component; ESR, erythrocyte sedimentation rate; LS, least squares; TNF, tumour necrosis factor.
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achieve signiﬁcantly better clinical responses over 6 months if
they receive rituximab rather than an alternative TNF inhibitor
as their second biological therapy. Similar to most non-
interventional studies, this open-label, observational study had
the limitation of substantial missing data, especially due to enrol-
ment of patients up to 4 weeks of starting the second biological
therapy, which resulted in many with a missing baseline. Because
the number and timing of visits were left to investigators’ discre-
tion, limited data were available to implement most of the imput-
ation methods appropriate to handle the withdrawal. However,
the completer results are broadly in agreement with recent
reports from national European registry studies. In a study of
patients with a single TNF inhibitor failure from the British
Society for Rheumatology Biologics Register, patients who
received rituximab as their second biological therapy were signiﬁ-
cantly more likely to achieve a European League Against
Rheumatism response and improvements in HAQ at 6 months
than those who received a second TNF inhibitor.23 Data from a
Swiss registry also indicated that rituximab treatment led to
better clinical outcomes in TNF-IR patients than an alternative
TNF inhibitor.16 17 The latter registry also recently reported that
rituximab and alternative TNF inhibitors were as effective in pre-
venting radiographical joint damage.24
The difference in clinical response at 6 months between ritux-
imab and alternative TNF inhibitor therapy in the present study
was observed in the primary effectiveness population, with dif-
ferences greatest among patients who discontinued their ﬁrst
TNF inhibitor because of inefﬁcacy. Patients who discontinued
because of intolerance showed no statistically signiﬁcant differ-
ence between rituximab and TNF inhibitor treatment. These
results are also consistent with previous studies, in which
TNF-IR patients who stopped because of primary inefﬁcacy
experienced lesser clinical responses with subsequent TNF
therapy than those who stopped because of secondary inefﬁcacy
or intolerance.25 26 Enhancement of clinical response to rituxi-
mab in patients who discontinued their ﬁrst TNF inhibitor
because of inefﬁcacy was observed in the Swiss registry.16
Patients exhibiting primary non-responsiveness to TNF inhibi-
tors are likely to have non-TNF-α-mediated disease and conse-
quently would be predicted to respond better to subsequent
therapy with an alternative mode of action. In contrast, patients
with secondary inefﬁcacy to TNF inhibitors may have lost
response because of the development of drug antibodies; these
patients would therefore be expected to exhibit a response to an
antigenically distinct treatment, whether within or distinct from
the previous class. The presence of drug antibodies was not
measured in this study. Finally, as most toxicity is independent
of a class effect, this explains the similarities between outcomes
with rituximab and TNF inhibitors in patients discontinuing
their initial TNF inhibitor because of intolerance.
A subanalysis according to serological status revealed that the
difference between rituximab and an alternative inhibitor was
further enhanced among the ∼80% of patients who were sero-
positive at baseline. In addition, as observed with the entire
primary effectiveness population, the improvement with rituxi-
mab versus TNF inhibitor treatment was signiﬁcantly greater in
seropositive patients with a previous TNF inhibitor failure due to
inefﬁcacy. Assessing the relative effectiveness of rituximab and
TNF inhibitor therapy in seronegative patients was limited by the
lower patient numbers in this subgroup. Interestingly, of patients
discontinuing a TNF inhibitor because of intolerance, seronega-
tive patients in both the rituximab and TNF inhibitor groups
exhibited numerically greater responses than those observed in
seropositive patients. In general, responses to rituximab in sero-
negative patients were numerically, but not statistically signiﬁ-
cantly, superior to those achieved with TNF inhibitors. Overall,
the results of the subanalysis by serological status concur with
recent studies reporting enhancement of clinical responsiveness
to rituximab in seropositive over seronegative patients.27–30 In
addition, serological status did not appear to inﬂuence respon-
siveness to TNF inhibitors in our study. Previous studies examin-
ing the inﬂuence of serological status on responsiveness to TNF
inhibitors yielded inconsistent results.31–34
The incidence and type of AEs observed with the two treat-
ments evaluated in this study were broadly similar and as
expected on the basis of the known safety proﬁles of these ther-
apies. Rituximab was associated with a slightly higher incidence
of serious AEs and serious infections, while there was one posi-
tive mycobacterium tuberculosis test in the TNF inhibitor
group.
In conclusion, these results from the SWITCH-RA study, con-
ducted in real-life conditions reﬂective of current clinical prac-
tice, indicate that, after discontinuation of a ﬁrst TNF inhibitor,
patients switching to rituximab achieved greater clinical effect-
iveness on average over 6 months compared with patients
switching to an alternative TNF inhibitor. This difference was
particularly evident among seropositive patients who discontin-
ued their initial TNF inhibitor because of inefﬁcacy.
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Adverse event
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Number of events (rate*) 25 (4.42) 9 (1.94)
95% CI of rate 2.86 to 6.52 0.89 to 2.68
Values are number (%).
*Per 100 patient-years.
TNF, tumour necrosis factor.
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